Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Extension Study of the Efficacy, Tolerability, and Safety of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency (IgPro20 EU Extension Study)

NCT00751621 is registered in ClinicalTrials.gov with CSL Behring as lead sponsor.

NCT NCT00751621
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00751621 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Extension Study of the Efficacy, Tolerability, and Safety of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency (IgPro20 EU Extension Study)
Lead sponsor
CSL Behring
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2008
Completion date
December 31, 2011
Enrollment
40 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

primary immunodeficiency (pid)